Results 1 to 10 of about 857,410 (384)

TYROSINE KINASE INHIBITORS AND INTERFERON

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance
Maria Dimou, P Panayiotidis
openaire   +5 more sources

TYROSINE KINASE INHIBITORS AND PREGNANCY

Mediterranean Journal of Hematology and Infectious Diseases, 2014
The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate.  The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients.
Alessio Perrotti, Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo de Fabritiis   +3 more
openaire   +6 more sources

Ocular Toxicity of Tyrosine Kinase Inhibitors [PDF]

Oncology Nursing Forum, 2016
To review common tyrosine kinase inhibitors, as well as their ocular side effects and management.
.A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms.Tyrosine kinase inhibitors can cause significant eye toxicity.
M. Davis
openaire   +4 more sources

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Zita Goliasova, Petr Michalek, Petr Michalek, Veronika Smidova, Zbynek Heger, Zbynek Heger, Vojtech Adam, Vojtech Adam, Petr Hodek, Tomas Eckschlager   +9 more
openaire   +4 more sources

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +4 more sources

Proteinuria and hypertension with tyrosine kinase inhibitors [PDF]

Kidney International, 2011
Tyrosine kinases are important for the development of pathological angiogenesis, a critical factor for survival and proliferation of tumor cells. Inhibition of tyrosine kinases either through targeted binding of its ligands or inhibition of its receptor has led to significant hindrance in angiogenesis and has improved survival for several cancers ...
Rajiv Agarwal, Rajiv Agarwal, Praveen Kandula   +2 more
openaire   +3 more sources

Development of inhibitors for protein tyrosine kinases [PDF]

Oncogene, 2000
In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the ...
Kit S. Lam, Fahad Al-Obeidi
openaire   +3 more sources

Tyrosine kinase inhibitors for diabetes [PDF]

Science-Business eXchange, 2008
UCSF researchers have shown that Novartis' Gleevec and Pfizer's Sutent, two small molecule tyrosine kinase inhibitors, prevented and even reversed type 1 diabetes in mice. It remains to be seen whether short-term use of this drug class can actually produce long-term therapeutic benefits safely.
openaire   +2 more sources

Latest progress in tyrosine kinase inhibitors

Oncotarget, 2014
Here we discuss the latest progress in development of some kinase inhibitors such as inhibitors of c-MET, LIM and Bcr-Abl kinases. Importantly, many oncogenic kinases signal via the mTOR pathway, suggesting a common target for drug combinations.
Valery A. Pospelov, Tatiana V. Pospelova
openaire   +4 more sources

Tyrosine Kinase Inhibitors in Lung Cancer [PDF]

Hematology/Oncology Clinics of North America, 2012
Identification of driver mutations in growth related protein kinases, especially tyrosine kinases, has led to clinical development of an array of tyrosine kinase inhibitors in various malignancies, including lung cancer. Improved understanding of tyrosine kinase biology has led to faster drug development, identification of resistance mechanisms, and ...
Giuseppe Giaccone, Arun Rajan, Anish Thomas   +2 more
openaire   +3 more sources